Global Blood Therapeutics (NASDAQ:GBT) Earns Neutral Rating From Cantor Fitzgerald
Global Blood Therapeutics (NASDAQ:GBT) Earns Neutral Rating From Cantor Fitzgerald
Cantor Fitzgerald reissued their neutral rating on shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) in a research note issued to investors on Wednesday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Global Blood Therapeutics' FY2022 earnings at ($4.55) EPS and FY2023 earnings at ($3.03) EPS.
坎托·菲茨杰拉德重新发布了对股票的中性评级 全球血液疗法（纳斯达克股票代码：GBT — 获取评级） PriceTargets.com在周三上午向投资者发布的研究报告中报道。坎托·菲茨杰拉德还公布了Global Blood Therapeutics的 FY2022 每股收益（4.55美元）和 FY2023 每股收益（3.03美元）的估计值。
GBT has been the subject of several other research reports. SVB Leerink cut Global Blood Therapeutics from an outperform rating to a market perform rating and set a $68.50 price target for the company. in a report on Tuesday, August 9th. Stifel Nicolaus reaffirmed a hold rating on shares of Global Blood Therapeutics in a report on Monday, August 8th. William Blair cut Global Blood Therapeutics from an outperform rating to a market perform rating in a report on Monday, August 8th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and increased their price target for the company from $40.00 to $72.00 in a report on Monday, August 8th. Finally, Wedbush cut Global Blood Therapeutics to a neutral rating in a report on Monday, August 15th. Twelve analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $65.50.
GBT 一直是其他几份研究报告的主题。SVB Leerink在8月9日星期二的一份报告中将Global Blood Therapeutics的评级从跑赢大盘评级下调至市场表现评级，并为该公司设定了68.50美元的目标股价。Stifel Nicolaus在8月8日星期一的一份报告中重申了对Global Blood Therapeutics股票的持有评级。威廉·布莱尔在8月8日星期一的一份报告中将Global Blood Therapeutics的评级从跑赢大盘下调至市场表现评级。Canaccord Genuity Group在8月8日星期一的一份报告中将Global Blood Therapeutics的评级从持有评级上调至买入评级，并将该公司的目标股价从40.00美元上调至72.00美元。最后，Wedbush在8月15日星期一的一份报告中将Global Blood Therapeutics下调至中性评级。十二位分析师对该股进行了持有评级，五位分析师对该股给予了买入评级。根据MarketBeat的数据，该股目前的平均评级为持有，共识目标价为65.50美元。
Global Blood Therapeutics Stock Performance
全球血液疗法股票表现
NASDAQ GBT opened at $67.99 on Wednesday. The company has a market cap of $4.59 billion, a PE ratio of -13.57 and a beta of 0.46. The stock's 50 day simple moving average is $58.27 and its 200-day simple moving average is $40.00. Global Blood Therapeutics has a 1-year low of $21.65 and a 1-year high of $73.02. The company has a debt-to-equity ratio of 4.92, a current ratio of 6.88 and a quick ratio of 6.17.
纳斯达克GBT周三开盘价为67.99美元。该公司的市值为45.9亿美元，市盈率为-13.57，beta值为0.46。该股的50天简单移动平均线为58.27美元，其200天简单移动平均线为40.00美元。Global Blood Therapeutics创下1年低点21.65美元，1年高点为73.02美元。该公司的债务与权益比率为4.92，流动比率为6.88，速动比率为6.17。
Insider Activity
内幕活动
In other news, insider Nazila Habibizad sold 4,678 shares of Global Blood Therapeutics stock in a transaction on Thursday, August 18th. The stock was sold at an average price of $67.19, for a total value of $314,314.82. Following the completion of the sale, the insider now directly owns 8,918 shares of the company's stock, valued at $599,200.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.90% of the company's stock.
在其他新闻方面，内部人士纳齐拉·哈比扎德在8月18日星期四的一笔交易中出售了4,678股Global Blood Therapeutics股票。该股的平均售价为67.19美元，总价值为314,314.82美元。出售完成后，知情人现在直接拥有该公司8,918股股票，价值599,200.42美元。此次出售是在向美国证券交易委员会提交的法律文件中披露的，该文件可在以下网址查阅 这个链接。内部人士拥有该公司4.90％的股票。
Institutional Investors Weigh In On Global Blood Therapeutics
机构投资者关注全球血液疗法
Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in shares of Global Blood Therapeutics by 75.6% in the first quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after buying an additional 650 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Global Blood Therapeutics in the first quarter valued at $448,000. Candriam Luxembourg S.C.A. boosted its holdings in Global Blood Therapeutics by 16.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 756,708 shares of the company's stock valued at $26,211,000 after purchasing an additional 108,369 shares during the period. Fairmount Funds Management LLC boosted its holdings in Global Blood Therapeutics by 59.1% in the first quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company's stock valued at $40,955,000 after purchasing an additional 439,307 shares during the period. Finally, Vestmark Advisory Solutions Inc. boosted its holdings in Global Blood Therapeutics by 44.3% in the first quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company's stock valued at $439,000 after purchasing an additional 3,892 shares during the period.
机构投资者最近修改了他们对该公司的持股。Nisa投资顾问有限责任公司在第一季度将其在Global Blood Therapeutics的股份增加了75.6％。Nisa Investment Advisors LLC在上个季度又购买了650股股票后，现在拥有该公司1,510股股票，价值52,000美元。Campbell & CO投资顾问有限责任公司在第一季度收购了Global Blood Therapeutics的新头寸，价值44.8万美元。Candriam Luxemboutics在第一季度将其在全球Blood Therapeutics的持股量增加了16.7％。在此期间又购买了108,369股股票后，Candriam Luxberg S.C.A. 现在拥有该公司756,708股股票，价值26,211,000美元。费尔蒙特基金管理有限责任公司在第一季度将其在Global Blood Therapeutics的持股量增加了59.1％。Fairmount Funds Management LLC在此期间又购买了439,307股股票后，现在拥有该公司1,182,307股股票，价值40,955,000美元。最后，Vestmark Advisory Solutions Inc.在第一季度将其在全球血液疗法的持股量增加了44.3％。在此期间又购买了3,892股股票后，Vestmark Advisory Solutions Inc.现在拥有该公司12,669股股票，价值43.9万美元。
About Global Blood Therapeutics
关于全球血液疗法
(Get Rating)
（获取评级）
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Blood Therapeutics, Inc是一家生物制药公司，致力于为服务不足的镰状细胞病（SCD）患者群体发现、开发和提供治疗方法。该公司提供Oxbryta片剂，这是一种口服，每天一次的SCD疗法。它还评估了针对青少年和儿科SCD患者的II期临床试验中单剂和多剂量Oxbryta的安全性和药代动力学。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- 免费获取 StockNews.com 关于全球血液疗法 (GBT) 的研究报告
- MarketBeat：本周回顾 9 月 19 日至 9 月 23 日
- 为什么特斯拉股票保持弹性？
- Crowdstrike 会从增加的每股收益指导中获得提振吗？
- 小型科技公司的裁员是房地产股的领头羊吗？
- 2 只值得关注的半导体股有望逆转
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《全球血液疗法日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Global Blood Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。